Therefore, HER2−/pHER2Y877+ BC patients would in theory require higher trastuzumab doses compared with HER2+ BC patients, while HER2+/pHER2Y877+ BC patients could receive a lesser dose. Here, ERBB2 is linked to breast cancer.